AMV 564

Drug Profile

AMV 564

Alternative Names: AMV564; T-564

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affimed Therapeutics
  • Developer Amphivena Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 09 Dec 2017 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral) before December 2017
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Myelodysplastic syndromes released by Amphivena Therapeutics
  • 29 Nov 2017 AMV 564 receives Orphan Drug status for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top